EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Neoadjuvant Intravesical Mitomycin C for NMIBC: A Phase III Single-Center, Open-Label Randomized Clinical Trial

Roberto Contieri, Alberto Saita, Marco Paciotti, Alessandro Uleri, Pier Paolo Avolio, Vittorio Fasulo iD, Ludovica Cella, Stefano Mancon iD, Federica Sordelli, Alessio Finocchiaro iD, Giuseppe Garofano, Paola Arena und 10 weitere

Cancers · 30.04.2026 · 18 (9) · 1444

DOI: 10.3390/cancers18091444 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cancers, online erschienen am 30.04.2026. Verfasst von Roberto Contieri und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objective: Transurethral resection of bladder tumor (TURBT) is the standard for non-muscle-invasive bladder cancer (NMIBC), yet recurrence rates remain high. This study evaluates the safety, tolerability, and efficacy of neoadjuvant intravesical mitomycin C (neoMMC) before TURBT in reducing recurrence and improving surgical outcomes. Methods: This randomized phase III trial enrolled patients with primary or recurrent NMIBC. Participants were randomized 1:1 to a neoadjuvant group receiving two instillations of MMC (day −14 and −7) before TURBT, or a control group undergoing standard TURBT without neoadjuvant treatment. The primary endpoint was 12-month recurrence-free survival (RFS). Secondary endpoints included surgical quality (complete resection, cauterization only, absence of residual tumor) and safety. Exploratory endpoints included histopathologic response and time to recurrence. Key Findings and Limitations: Among 95 patients (48 neoMMC, 47 controls), baseline characteristics were balanced. After a median follow-up of 19.4 months, recurrences occurred in 9 StA and 4 NeoA patients, with one progression to MIBC in the NeoA arm. RFS did not differ significantly between groups at 12 or 18 months. Neoadjuvant MMC was well tolerated, with only grade 1–2 AEs. Exploratory microbiota analyses suggested that neoadjuvant MMC modulated urinary microbial diversity and was associated with a microbiota profile more similar to that observed in non-recurrent patients. Limitations include single-center design and relatively short follow-up. Conclusions and Clinical Implications: Neoadjuvant intravesical MMC before TURBT was feasible and well tolerated in patients with NMIBC, with no unexpected safety signals. In this prematurely terminated and underpowered trial, no significant improvement in RFS was observed. Larger adequately powered studies are needed to clarify the oncologic efficacy of this approach.

Schlagwörter

Stichwörter der Autor:innen

immunogenic cell deathintravesical chemotherapymitomycin Cneoadjuvant therapynon-muscle invasive bladder cancerrecurrence-free survival

Autor:innen und Institutionen

  • Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy.
  • Department of Urology, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy.
  • IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, Italy.
  • Department of Pathology, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy.

ORCID-Profile: Vittorio Fasulo, Stefano Mancon, Alessio Finocchiaro, Miriam Cieri, Giovanni Lughezzani, Massimo Lazzeri

Zitieren

APA

Contieri, R., Saita, A., Paciotti, M., Uleri, A., Avolio, P. P., Fasulo, V., Cella, L., Mancon, S., Sordelli, F., Finocchiaro, A., Garofano, G., Arena, P., Pozzi, C., Gatti, A., Lizier, M., Cieri, M., Colombo, P., Buffi, N. M., Lughezzani, G., …, & Hurle, R. (2026). Neoadjuvant Intravesical Mitomycin C for NMIBC: A Phase III Single-Center, Open-Label Randomized Clinical Trial. Cancers, 18(9), 1444. https://doi.org/10.3390/cancers18091444

Vancouver

Contieri R, Saita A, Paciotti M, Uleri A, Avolio PP, Fasulo V, et al. Neoadjuvant Intravesical Mitomycin C for NMIBC: A Phase III Single-Center, Open-Label Randomized Clinical Trial. Cancers. 2026;18(9):1444. doi:10.3390/cancers18091444

BibTeX
@article{Contieri2026,
  author = {Contieri, Roberto and Saita, Alberto and Paciotti, Marco and Uleri, Alessandro and Avolio, Pier Paolo and Fasulo, Vittorio and Cella, Ludovica and Mancon, Stefano and Sordelli, Federica and Finocchiaro, Alessio and Garofano, Giuseppe and Arena, Paola and Pozzi, Chiara and Gatti, Andrea and Lizier, Michela and Cieri, Miriam and Colombo, Piergiuseppe and Buffi, Nicolò Maria and Lughezzani, Giovanni and Casale, Paolo and Lazzeri, Massimo and Hurle, Rodolfo},
  title = {Neoadjuvant Intravesical Mitomycin C for NMIBC: A Phase III Single-Center, Open-Label Randomized Clinical Trial},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {9},
  pages = {1444},
  doi = {10.3390/cancers18091444}
}
Kostenlos starten →